Allogeneic transplantation using non-myeloablative transplant regimens

Best Practice & Research. Clinical Haematology
M Battiwalla, J Barrett

Abstract

Reduced intensity (non-myeloablative) stem cell transplant (NST) preparative regimens are being increasingly used to exploit the curative potential of allogeneic stem cell transplantation without the morbidity and mortality associated with conventional transplantation. Growing confidence in the power of the allogeneic graft-versus-malignancy (GVM) effect makes such an approach attractive. Lower intensity transplants increase the degree of mixed chimerism, both in T cell and myeloid cell lineages. Currently a variety of NST treatment approaches are being developed and in this chapter their safety profile and the immunological characteristics of the mixed chimeric state are described. Results of NST in specific disease categories are still limited but the NST approach appears to have promise in the treatment of both haematological and non-haematological malignancies because of the benefit of low toxicity coupled with a strong graft-versus-malignancy effect. NST regimens are also being explored in high-risk patients with non-malignant disorders. However, at present, there is insufficient data to determine whether NST should replace standard myeloablative transplants in specific disease groups. With their low toxicity, NST are well...Continue Reading

References

Feb 15, 1990·The New England Journal of Medicine·G LucarelliF Albertini
Oct 1, 1993·Current Opinion in Immunology·J L Ferrara
Jun 1, 1997·Immunological Reviews·H E Heslop, C M Rooney
Jun 3, 1999·The New England Journal of Medicine·E C GuinanJ G Gribben
Jul 7, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·M R PelotM Sykes
Aug 28, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·P A McSweeney, R Storb
Mar 21, 2000·Bone Marrow Transplantation·A M CarellaR Storb
May 8, 2000·Journal of Clinical Immunology·R K BurtA E Traynor
Jun 23, 2000·The Journal of Clinical Investigation·Y FuchimotoD H Sachs
Jul 25, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·T R SpitzerM Sykes
Nov 25, 2000·British Journal of Haematology·J Barrett, R Childs
May 5, 2001·Immunity·M Sykes

❮ Previous
Next ❯

Citations

May 5, 2009·Seminars in Oncology Nursing·Nonniekaye Shelburne, Margaret Bevans
Apr 3, 2007·Transfusion Medicine Reviews·Martin H BluthNoga Manny
Nov 25, 2003·Hematology·A John BarrettNelson Chao
Feb 26, 2003·Current Opinion in Oncology·Leo LuznikEphraim J Fuchs
Sep 10, 2011·Drugs·Katayoun Rezvani, Hugues de Lavallade
Jan 22, 2009·Mycopathologia·Muhammad A Mir, Minoo Battiwalla
Sep 27, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Karlie JonesGabriela Dveksler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.